Assessment Of Serum And Tissue Levels Of Cold-Inducible RNA-Binding Protein In Patients With Lichen Planus

Status: Recruiting
Location: See location...
Study Type: Observational
SUMMARY

Lichen planus (LP) is a chronic inflammatory mucocutaneous disease of unknown etiology. Pathogenesis of LP is not completely understood, but it's considered a T-cell-mediated autoimmune disease. Cold-inducible RNA binding protein (CIRP or CIRBP) is a member of the glycine-rich RNA-binding protein family, Recent studies proved that CIRP acts as a tumor promoter through its actions on different cellular proliferation levels, Recently, the role of the damage associated molecular proteins and cytokines was highlighted in the pathogenesis of many disorders including psoriasis, alopecia areata, vitiligo, rheumatoid arthritis, other autoimmune diseases as well as several types of cancer. The aim of this study is to compare serum and tissue levels of CIRP in patients with LP and healthy controls.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 60
Healthy Volunteers: t
View:

• Patients from both sexes aged 18 - 60 years, having clinical and dermoscopic confirmed LP and did not receive any topical or systemic treatment in the last 3 months for LP.

Locations
Other Locations
Egypt
Aya Ahmed Elsayed
RECRUITING
Sohag
Contact Information
Primary
Aya A Elsayed, Msc
aya_shando@yahoo.com
00201060094631
Backup
Aya A Alshandawely, Msc
aya_shando@yahoo.com
00201061691091
Time Frame
Start Date: 2024-02
Estimated Completion Date: 2025-10
Participants
Target number of participants: 80
Treatments
Lichen Planus Cases
40 cases with lichen planus from who skin biopsies and blood samples will be taken to assess cold inducible RNA binding protein levels in both tissues and serum.
Healthy control group
40 healthy controls from who skin biopsies and blood samples will be taken to assess serum and tissue levels of cold-inducible RNA binding protein and compare them to active cases.
Sponsors
Leads: Sohag University

This content was sourced from clinicaltrials.gov